Metabolic and weight research

Weight Management Bundle

A triple-agonist incretin-pathway research peptide, paired with an oral metabolic small molecule.

Purpose

Pairs a triple GIP/GLP-1/glucagon receptor agonist (Retatrutide) with an oral NNMT-inhibitor small molecule (5-Amino-1MQ) — an incretin-pathway option alongside a distinct oral mechanism, both studied in fat-metabolism research.

Best For

Researchers studying glycemic-control and fat-metabolism pathways across an incretin-receptor agonist and an oral small-molecule angle.

Included Peptides

Retatrutide

Triple GIP/GLP-1/glucagon receptor agonist studied in human clinical trials for metabolic and weight research.

Protocol published

5-Amino-1MQ

Small-molecule NNMT inhibitor studied for fat-metabolism and cellular-energy research.

Protocol published

Expected Outcomes

Glycemic-control research
Weight-management studies
Fat-metabolism and NNMT-pathway research

Timeline

Retatrutide: 12–24 week research cycles, once weekly. 5-Amino-1MQ: per oral research protocol.

Protocol Preview

View the full research protocol — reported dosing, evidence and references — for each included peptide:

Retatrutide protocol →5-Amino-1MQ protocol →

Recommended Companion Products

Bacteriostatic Water

Sterile, USP-grade water preserved with 0.9% benzyl alcohol, used to reconstitute lyophilized (freeze-dried) peptides. This is a diluent, not an active peptide.

Shop This Bundle

Retatrutide

5-Amino-1MQ

Available following assessmentStart Assessment →

Start Your Assessment

Complete the Regenexa AI assessment to get a personalized protocol that accounts for this goal.

Start assessment →

Prefer to just ask? Chat with Regenexa AI →

This bundle is an educational grouping of existing research products, not a combined or new formulation. Each item ships and is documented exactly as it is when purchased individually.